After many years of research and development, ATANIS Biotech AG was incorporated as a spinoff of the University of Bern in June 2021. The four co-founders Noemi Zbären, Jean-Pierre Kinet, Thomas Kaufmann and Alexander Eggel bring >70 years of combined experience in basic and clinical allergy research, cell and molecular biology and diagnostic assay development to the company and have published >250 publications in peer-reviewed high-impact journals.
Our team
Prof. Dr. Jean-Pierre Kinet
Co-Founder & CEO

Erwan Eriau
Chief Operating Officer

Jonathan Friedlander
Chief Business Officer

Dr. Charlène Niogret
Head of Development & Regulatory Affairs

Dr. Saskia Agten-Brunner
Head of Diagnostic Laboratory

Robin van Brummelen
Head of Research Services

Dr. Julia Tischler
Head of Process Technology

Antonia Ferreira
Development Scientist

Giulia Fuchs
Research Associate

Marianne Zwicker
Laboratory Manager

Dr. Lucas Degrugillier
Development Scientist

Eloi Thauvin
Manufacturing and Improvement Engineer

Joëlle Schläfli
Manufacturing and Quality Control Engineer

Prof. Dr. Thomas Kaufmann
Co-Founder & Scientific Advisor

Prof. Dr. Alexander Eggel
Co-Founder & Scientific Advisor

Jascha Forster
Board member

Mária Husvéth-Tóth
Research Assistant

Dr. Zahra Gharailoo
Research Scientist

Jessica Almeida Oliveira
Development Associate

Juliette Assenmacher
Development Associate

Melanie Devjayanth
QA Release Assistant

Our Customers
Our customer base reaches from highly established industrial partners to individual research groups.

Excellergy
Excellergy is a biotechnology company developing new therapeutic modalities in various diseases.
Our Investors
Are you interested to invest in ATANIS Biotech AG or to financially support us? Please get in touch!